Characterization of a dCTP Transport Activity Reconstituted from Human Mitochondria*

Edward G. BridgesDagger , Zaoli JiangDagger , and Yung-chi Cheng§

From the Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520

    ABSTRACT
Top
Abstract
Introduction
References

A protein fraction of mitochondria from human acute lymphocytic leukemia cells, which could be reconstituted into proteoliposomes to have dCTP transport activity, has been partially purified by hydroxyapatite and blue Sepharose chromatography. The dCTP transport activity in proteoliposomes was time-dependent and could be activated by Ca2+ and to a lesser extent by Mg2+. None of the other divalent cations tested could activate the transport activity. The Km value of dCTP in the presence of Ca2+ was shown to be 3 µM. dCDP but not dCMP or dCyd could inhibit the transport activity. Other deoxynucleoside triphosphates could also inhibit the uptake of dCTP with the potency dGTP = dATP > TTP. Although ATP could competitively inhibit dCTP uptake with a Ki value of 8 µM, the reconstituted dCTP uptake activity was not sensitive to the ATP/ADP carrier inhibitor atractyloside or the sulfhydryl reagent N-ethylmaleimide. This suggests that the dCTP transport system studied is not the same as the ATP/ADP carrier. In conclusion, these studies describe the first functionally reconstituted mitochondrial carrier that displays an efficient transport activity for dCTP.

    INTRODUCTION
Top
Abstract
Introduction
References

The inner membrane of mitochondria normally possesses very low electrophoretic permeability to most molecules. However, through the action of specific transport systems, the inner mitochondrial membrane is selectively permeable to a number of co-factors, metabolites, and nucleotides (1, 2). The AAC1 is the only mitochondrial nucleotide carrier successfully isolated and reconstituted in an active state (3). The AAC is highly selective for ADP and ATP, mediating the import of ADP from the cytoplasm and export of matrix ATP. The ATP-Mg/Pi carrier is another nucleotide transport activity that has been described in isolated mitochondria (4) but has not been successfully isolated. Another member of the family of anion transport proteins that reside within the mitochondrial inner membrane is the phosphate carrier that catalyzes transport of inorganic phosphate into the mitochondrial matrix, where the phosphate is utilized for phosphorylating ADP to ATP (5).

The existence of a mechanism for mitochondrial dNTP uptake has been suggested by DNA synthesis experiments using isolated mitochondria (6-8). These studies indicated that exogenous dNTPs could be utilized by isolated mitochondria to synthesize mitochondrial DNA. In addition, based on previous studies from our laboratory, antiviral nucleoside analog triphosphates in mitochondria appear to originate from the cytoplasm (9). In these studies, the absence of 2',3'-dideoxycytidine-induced mitochondrial toxicity in cytoplasmic dCyd kinase-deficient cells suggested that the cytoplasmic-formed metabolite 2',3'-dideoxycytidine triphosphate is the nucleotide source in the inhibition of mitochondrial DNA synthesis. Thus, the 2',3'-dideoxycytidine triphosphate metabolites inside mitochondria appear to originate from the cytoplasm. However, the experimental evidence supporting the existence of a dNTP carrier in intact mitochondria is only circumstantial and not definitive as for other mitochondrial metabolite carriers.

The final proof for the existence of a carrier protein is its isolation and functional reconstitution. To that end, we demonstrate that upon incorporation into lipid vesicles, partially purified mitochondrial protein catalyzes dCTP uptake. This transport activity displays unique substrate specificity and inhibitor sensitivity from that previously described for mitochondrial anion transporters. To our knowledge, this is the first report of a substantially purified preparation of this class of mitochondrial carrier activity in functional form.

    EXPERIMENTAL PROCEDURES

Chemicals-- Hydroxyapatite (Bio-Gel HPT) was purchased from Bio-Rad. Blue Sepharose and Sephadex G-50 were from Amersham Pharmacia Biotech. alpha -32P-Labeled nucleotides were from Amersham Pharmacia Biotech. Soybean asolectin (L-alpha -phosphatidylcholine), cholesterol, Triton X-114, Dowex 1 × 4 (100-200 mesh, chloride form), atractyloside, and nucleotides were from Sigma.

Preparation of [gamma -32P]dCTP-- Nucleoside diphosphate kinase (from Baker's yeast; Sigma) was used to prepare [gamma -32P]dCTP from dCDP as follows. A 1-ml mixture containing 10 units of nucleoside diphosphate kinase, 2 mM [gamma -32P]GTP (100 µCi), and 0.5 mM dCDP in 150 mM Tris acetate, pH 7.5, and 10 mM MgCl2 was incubated at 37 °C for 10 min. The reaction was stopped by the addition of 3 volumes of ice-cold methanol and incubated on ice for 15 min. After centrifugation at 14,000 × g for 10 min, the supernatant containing [gamma 32P]dCTP was evaporated to dryness and resuspended in 500 µl of water. The mixture containing dCDP, GDP, [gamma -32P]GTP, and [gamma -32P]dCTP was chromatographed by ion exchange HPLC using a Whatman Partisil-SAX column (4.6 mm × 25 cm) at a flow rate of 1 ml/min. The nucleotides were resolved with a gradient consisting of water to 30 mM buffer (potassium phosphate, pH 6.7) from 0 to 10 min, 30-150 mM buffer from 10 to 15 min, 150 mM buffer from 15 to 50 min, and 300 mM buffer from 50 to 80 min. Peaks were identified by authentic standards, and the peak corresponding to [gamma -32P]dCTP was collected. The purified [gamma -32P]dCTP was diluted 5-fold with water, placed over a DEAE-Sephadex A-25 column (2-ml bed volume), and washed with 20 ml of water to remove the phosphate buffer, and the [gamma -32P]dCTP was eluted with 10 ml of ammonium formate (500 mM). The eluted sample was freeze-dried to remove the ammonium formate and resuspended to a volume of 2 ml in water. The purity of [gamma 32P]dCTP was verified by ion exchange HPLC as described above, and the radiospecificity was determined to be 90 µCi/mmol.

Preparation of Mitochondria and Partial Purification of Proteins with dCTP Transport Activity-- Mitochondria were isolated from acute lymphocytic leukemia cells after leukophoresis of a patient in blast crisis and further purified on a discontinuous sucrose gradient as described previously (9). Frozen mitochondria (100-150 mg) were solubilized for 10 min on ice in 10 ml of a buffer containing 20 mM Hepes (pH 7.0), 1% Triton X-114, 150 mM Na2SO4, 1 mM phenylmethylsulfonyl fluoride, and 1 mM benzamidine. The detergent was separated from the aqueous phase by centrifugation at 280,000 × g for 1 h at 4 °C. The upper aqueous phase was decanted, and the detergent phase was resuspended to 10 ml in 20 mM Hepes (pH 7.0), 1 mM phenylmethylsulfonyl fluoride, and 1 mM benzamidine (buffer B). The detergent extract was applied to an HPT column (1 g of dry HPT/20 mg of protein) connected in tandem with a blue Sepharose column (1 ml of Blue Sepharose/2 mg of protein) equilibrated with buffer B. The unbound protein-containing fraction was eluted from the tandem columns with buffer B.

Preparation of Proteoliposomes-- Asolectin was further purified as described (10). For use in transport studies, cholesterol (120 mg/ml final concentration) was added to the asolectin (200 mg/ml final concentration). Cholesterol has been reported to prevent protein-mediated leakage in reconstituted proteoliposomes (11). The asolectin was stored in chloroform under nitrogen in a light proof container at -20 °C. Immediately before use, an aliquot of asolectin was dried under a stream of nitrogen. Following the addition of 2 ml of 20 mM Hepes (pH 7.0), the lipid was dispersed by sonication (Branson Sonifier 250; microtip output control = 4; 80% duty cycle; on ice) until the mix appeared transparent.

Aliquots of freshly isolated protein fractions (typically 0.3 mg) were mixed with lipid vesicles (55 mg) to a final volume of 1 ml. This mixture was vortexed and then rapidly frozen in liquid nitrogen. For ATP/ADP exchange reactions and dCTP efflux experiments, proteoliposomes were prepared in the presence of 100 µM ADP and 20 µM [alpha -32P]dCTP, respectively. These proteoliposomes could be stored at -80 °C up to 5 days without appreciable loss of dCTP transport activity. Immediately prior to assay, the samples were freeze-thawed twice (total of three cycles) using liquid nitrogen and thawed a final time in an ice-water bath followed by sonication (Branson Sonifier 250; microtip output control = 2; 70% duty cycle; 30 burst; total sonication time = 25 s; on ice). For ATP/ADP exchange reactions and dCTP efflux experiments, external ADP and [alpha -32P]dCTP, respectively, were removed by passing the proteoliposomes over an ion exchange column (Dowex; 1 × 3.5 cm) equlibrated with 20 mM Hepes (pH 7.0) at 4 °C. The first 1 ml of the turbid eluate from the Dowex column was collected and then used for transport experiments. A heterogeneous population of large, primarily unilamellar proteoliposomes suitable for transport studies are generated by this general freeze-thaw-sonicate procedure (12-15).

Assay Conditions for dCTP Uptake-- All measurements of nucleotide uptake into reconstituted proteoliposomes were carried out at 37 °C. Transport was initiated by the addition of 4 µl of radiolabeled substrate (typically [alpha -32P]dCTP, 10 µM final concentration, 30 Ci/mmol) to 190 µl of proteoliposomes in a final volume of 200 µl. For competition assays, competitor was added to the desired concentration to the proteoliposome mix before the radiolabeled substrate. After the desired incubation time, the reaction mixture was placed over a Dowex ion exchange column (1 × 3.5 cm) equilibrated with 20 mM Hepes (pH 7.0) at 4 °C in order to remove the external radioactivity not transported into proteoliposomes. The liposomes were eluted with 4 ml of ice-cold equilibration buffer, collected in 16 ml of scintillation fluid, vortexed, and counted. Subtracting values obtained when a 100-fold molar excess of nonradiolabeled substrate was added 2 min prior to the radiolabeled substrate made corrections for nonspecific uptake of radioactivity. For efflux experiments, external radioactivity was removed by passing the samples through a Dowex column and collecting and counting the liposomes as described above. The transport activity was calculated by subtracting the experimental values from the control values (efflux at 4 °C).

    RESULTS AND DISCUSSION

Mitochondria possess a variety of specific carrier systems for the transport of metabolites across the inner mitochondria membrane. Because of the importance of mitochondrial toxicity in nucleoside analog chemotherapy (for a review, see Ref. 16), we have sought to extend our knowledge about dCTP uptake into mitochondria. Our procedure for isolation and reconstitution of active dCTP transport from human mitochondria consisted of three basic steps. First, sucrose gradient isolated mitochondria were extracted with Triton X-114. Second, hydrophobic membrane proteins in the detergent were separated from the aqueous phase. Finally, the detergent phase containing solubilized membrane proteins was chromatographed on HPT and blue Sepharose. When applying these conditions to mitochondria from acute lymphocytic leukemia cells, the activity of dCTP transport was significantly enriched, but it remains a heterogeneous mixture of proteins.

In Table I the activity of the protein obtained by blue Sepharose chromatography relative to that of the HPT chromatography is reported. For comparison, we report also the data on the total mitochondrial membrane extract. However, reconstitution of a total membrane extract in liposomes and its comparison with the data obtained from a smaller number of proteins after chromatography should be done with caution and may not be fully reliable because of differences in protein-protein interactions, liposome size, and passive permeabilities. Uptake of [alpha -32P]dCTP could be detected in proteoliposomes reconstituted using crude mitochondrial protein extracts and detergent phase membrane proteins with a specific activity of 2.8 and 18 pmol/min/mg protein, respectively. However, only minimal dCTP transport activity could be detected in proteoliposomes using aqueous phase proteins after detergent phase separation. Approximately 180- and 90-fold increases in the specific activity of dCTP uptake in proteoliposomes compared with crude extracts were obtained after HPT and blue Sepharose chromatography, respectively. The decrease in specific activity after blue Sepharose chromatography compared with HPT elutes may indicate the presence of multiple dCTP transport activities resolved by blue Sepharose. Alternatively, this result may suggest the removal of a protein(s) component of a multisubunit complex responsible for dCTP transport. Furthermore, there is a large increase in the total activity recovered in the HPT eluate (i.e. 965%) relative to the starting material. The recovery of activity greater than the starting material may reflect the removal of an inhibitor or interfering activity. Further studies will be required to define the role of these factors in the above observations.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Partial purification of the dCTP carrier activity from human acute lymphocytic leukemia mitochondria
Sucrose gradient isolated mitochondria were used as a starting material. Protein fractions were incorporated into phospholipid vesicles as described under "Experimental Procedures." Uptake was started by the addition of 10 µM [alpha -32P]dCTP to proteoliposomes in a buffer containing 20 mM Hepes (pH 7.0), 0.2 mM EDTA, and 2 mM CaCl2. The dCTP uptake activity was measured for 1 min at 37 °C.

Hydroxyapatite chromatography is important because it offers a large single purification step common to mitochondrial anion transporters (17-23). Under the conditions described under "Experimental Procedures," the reconstituted protein eluate after HPT chromatography contained atractyloside-sensitive AAC activity in addition to dCTP transport activity (data not shown). To improve the purification of the dCTP carrier activity, the protein eluate after HPT chromatography was applied to a blue Sepharose column to remove the AAC activity (24). Table II shows that after HPT and blue Sepharose chromatography the internalized ADP as a counterion did not stimulate ATP uptake in reconstituted proteoliposomes. This is in contrast to HPT protein eluates reconstituted into proteoliposomes, where internalized ADP dramatically increased ATP uptake (data not shown). Furthermore, ATP uptake in proteoliposomes was observed after HPT and blue Sepharose chromatography but was not sensitive to the AAC inhibitor atractyloside. These results demonstrate that the reconstituted protein eluate after HPT and blue Sepharose chromatography is capable of ATP transport, but this activity is not associated with AAC activity. Further studies will be required to determine whether one or more proteins are present that play a role in dCTP and ATP transport.

                              
View this table:
[in this window]
[in a new window]
 
Table II
ATP uptake in proteoliposomes
The protein eluate after HPT and blue Sepharose chromatography was obtained and reconstituted as described under "Experimental Procedures." For ATP/ADP exchange reactions, proteins were reconstituted in the presence of 100 µM ADP. Uptake reactions were initiated by the addition of 10 µM [alpha -32P]ATP. dCTP was added 2 min prior to the addition of radiolabeled substrate as indicated. Means and S.D. values from three separate experiments are presented.

The unbound protein fraction from HPT and blue Sepharose chromatography was functionally characterized for dCTP transport activity after incorporation into liposomes. To obtain a base line of transport activity in the absence of divalent cations, the effect of EDTA on transport using 10 µM [32P]dCTP in reconstituted proteoliposomes was measured (Fig. 1A). A significant dose-dependent decrease in dCTP uptake was observed with a maximum effect at 0.2 mM EDTA. We next measured the effect of 1 mM divalent cations on dCTP uptake in the presence of 0.2 mM EDTA (Fig. 1B). Mn2+ and Zn2+ had a negligible effect, while Cu2+ and Co2+ inhibited dCTP uptake. However, Ca2+ dramatically increased dCTP uptake, whereas Mg2+ and Ni2+ moderately increased uptake. In addition, NaCl and KCl were observed to have no effect on dCTP uptake (data not shown). The effects of Ca2+ and Mg2+ were further investigated in Fig. 1C. A dose-dependent increase in dCTP uptake was noted with Ca2+ that was saturable at about 2 mM (an 8-fold increase), whereas the effect of Mg2+ was less dramatic (a 2.5-fold increase).


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 1.   Optimization of dCTP uptake. Proteoliposomes were prepared from the protein eluate after HPT and blue Sepharose chromatography as described under "Experimental Procedures." Uptake was initiated by the addition of 10 µM [alpha -32P]dCTP for 1 min. A depicts the effect of EDTA on the uptake of dCTP by proteoliposomes in the presence of 20 mM Hepes (pH 7.0). B illustrates the effect of divalent cations on the dCTP carrier activity in 20 mM Hepes (pH 7.0) and 0.2 mM EDTA. Vesicles were incubated for 1 min with the indicated additions at a concentration of 2 mM before initiating uptake. The control value of dCTP uptake in the absence of divalent cations was 23 pmol/min/mg of protein. C illustrates the effect of Mg2+ and Ca2+ on dCTP uptake. Vesicles were incubated for 1 min with 20 mM Hepes (pH 7.0), 0.2 mM EDTA, and MgCl2 (open circle ) or CaCl2 (bullet ) as indicated.

What effect is Ca2+ having to stimulate dCTP transport activity? The transport assay described in this study consisted of several components that, in principle, could all be targets for the cations: negatively charged phospholipids, the negatively charged substrate dCTP, and the inserted carrier protein. Interaction of Ca2+ with the anionic substrate dCTP is questionable because of the large discrepancy in the actual concentrations used. Interestingly, the affinity of Mg2+ for ATP has been reported to be about 10 times higher than that of Ca2+ (25). If Mg2+ interacts with the triphosphate moiety of dCTP similar to that of ATP to stimulate dCTP transport in reconstituted proteoliposomes, the activation effect of Mg2+ should be seen at lower concentrations. Second, the results presented in this paper cannot simply be due to surface charge screening of the phospholipid vesicles, since there are significant differences with respect to the stimulation power between the various cations tested. Finally, although the protein may be the most reasonable choice as the target of the activation by Ca2+, further studies will be required to address this issue.

The effect of protein concentration on the reconstitution of the dCTP transport activity was investigated by progressively increasing the protein concentration in the reconstitution mix while keeping the lipid concentration constant (55 mg/ml). Increasing the protein concentration from 0.05 to 0.4 mg/ml resulted in a parallel increase in the transporter-mediated uptake of [32P]dCTP (Fig. 2A). There also was a slight increase in the background rate of uptake with increasing protein concentration (<2 pmol/min at 0.4 mg/ml protein), but this increase was much less pronounced than the increase in the rate of protein-mediated uptake. From these experiments, we selected 0.3 mg/ml protein as an optimum condition to characterize dCTP uptake.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 2.   Characterization of dCTP uptake. Proteoliposomes were prepared from the protein eluate after HPT and blue Sepharose chromatography as described under "Experimental Procedures." Vesicles were incubated with [32P]dCTP in the presence of 20 mM Hepes (pH 7.0), 2 mM CaCl2, and 0.2 mM EDTA. A illustrates the effect of protein concentration on the uptake of dCTP by proteoliposomes. Uptake was initiated by the addition of 10 µM [alpha -32P]dCTP for 1 min. The protein concentration of the initial reconstitution mixture was varied from 0.05 to 0.4 mg/ml. B illustrates the time- and temperature-dependent uptake of [alpha -32P]dCTP by proteoliposomes reconstituted with 0.3 mg/ml protein. Uptake was initiated by the addition of 10 µM [alpha -32P]dCTP. Vesicles were incubated for the indicated times at 37 °C (bullet ) or 4 °C (open circle ). Proteoliposomal uptake of [alpha -32P]dCTP is plotted as pmol of [alpha -32P]dCTP accumulated per milligram of proteoliposomal protein. C illustrates the time-dependent efflux of dCTP in proteoliposomes (reconstituted with 0.3 mg/ml protein) loaded with 20 µM [alpha -32P]dCTP as described under "Experimental Procedures." Transport was initiated by incubation at 37 °C. D illustrates the time- and temperature-dependent uptake of [gamma -32P]dCTP by proteoliposomes reconstituted with 0.3 mg/ml protein. Uptake was initiated by the addition of 20 µM [gamma -32P]dCTP and the vesicles incubated for the indicated times at 37 (bullet ) or 4 °C (open circle ).

In Fig. 2B the dCTP uptake catalyzed by mitochondrial protein reconstituted into liposomes has been plotted as a function of time. There is an apparent initial rapid component occurring within 1 min and a slower uptake component that reached a steady state within 5-10 min. A temperature dependence in dCTP uptake is also observed with negligible [32P]dCTP uptake when the proteoliposomes are incubated at 4oC. Subsequent experiments were conducted at 1 min to assess the initial uptake of dCTP in reconstituted proteoliposomes. Because the insertion of protein in the lipid vesicle is in a random orientation, unidirectional transport in both directions may explain the time-dependent change in the transport rate. To measure the efflux of dCTP, proteoliposomes were preloaded with [alpha -32P]dCTP. Fig. 2C illustrates a time-dependent efflux of [alpha -32P]dCTP from proteoliposomes similar to that observed for influx. To directly address if dCTP is transported without prior breakdown, dCTP was radiolabeled with 32P in the gamma -position only and used for uptake studies. Fig. 2D illustrates the time- and temperature-dependent uptake of [gamma -32P]dCTP. Under these conditions, [gamma -32P]dCTP uptake decreases in the presence of excess nonradiolabeled dCTP.2 However, a 10-fold molar excess of inorganic phosphate has no effect on [gamma -32P]dCTP uptake, suggesting that protein-mediated uptake of 32P-labeled inorganic phosphate (e.g. the phosphate transporter) plays no role in the observed transport activity.2 Thus, it is unlikely than dCTP is broken down before uptake into proteoliposomes. In addition, the exchange of a counterion (including dCDP or ADP) for dCTP in reconstituted proteoliposomes, similar to that for ATP and ADP in the AAC nucleotide transport system, has not been observed.2

We have thus far demonstrated the transport activity of reconstituted mitochondrial protein by measuring the uptake of radioactive substrate into proteoliposomes. With this assay method, the amount of substrate taken up can be measured, but it is not possible to obtain precise initial kinetic parameters because the radioactive substrate remaining outside the proteoliposomes has to be removed before the radioactive substrate transported inside the vesicles can be measured. Further studies were performed to elucidate a dose-response curve for dCTP uptake in proteoliposomes. The value obtained from a Lineweaver-Burk plot (Fig. 3) indicated an apparent Km of 3 µM. The inhibition of dCTP uptake in proteoliposomes by ATP was also studied. Fig. 3 demonstrates that ATP competitively inhibits dCTP uptake. The Ki value was estimated to be 8 µM by a replot of the slopes versus the ATP concentration. Numerous studies in cell culture, particularly that of the T-lymphoblastic cell line CEM, have demonstrated dCTP intracellular pool sizes ranging from 8 to 38 µM (26-30). Whereas CEM cells are rapidly dividing cells in culture, another study using peripheral blood lymphocytes reported a dCTP pool size of 1.5 µM in quiescent cells and 18 µM in phytohemagglutinin-activated lymphocytes (31). Thus, the mitochondrial dCTP transport activity reported herein may be significant within the range of these reported intracellular dCTP concentrations.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 3.   Interaction of dCTP with reconstituted proteoliposomes and inhibition by ATP. Proteoliposomes (0.3 mg/ml protein) were prepared after HPT and blue Sepharose chromatography as described under "Experimental Procedures." Transport was initiated by the addition of [alpha -32P]dCTP at the indicated concentrations for 1 min in the presence of 20 mM Hepes (pH 7.0), 2 mM CaCl2, and 0.2 mM EDTA. The data are presented as a double-reciprocal plot of dCTP uptake. Velocity is expressed as pmol of dCTP uptake/min/mg of protein. The figure illustrates the dependence of the rate of dCTP uptake in proteoliposomes on substrate concentration and the inhibition of dCTP uptake in reconstituted proteoliposomes by ATP. Vesicles were incubated with [alpha -32P]dCTP in the presence of ATP. Velocity is expressed as pmol of dCTP uptake/min/mg of protein. Concentrations of ATP were 0 (bullet ), 5 (open circle ), 10 (black-square), and 20 () µM. The Ki value for ATP was determined by replot of the slopes as shown in the inset. These data represent the means and S.D. values of at least three experiments in duplicate.

The substrate specificity of this novel mitochondrial carrier activity was examined by investigating the ability of dCTP and its derivatives to inhibit uptake of the unidirectional, inward flux of 10 µM [32P]dCTP (Table III). If [32P]dCTP were broken down to [32P]dCDP or [32P]dCMP for transport, we would expect excess dCDP or dCMP to decrease uptake by dilution of the radiospecificity of [32P]dCDP or [32P]dCMP derived from the action of phosphatase present in the preparation. Excess unlabeled dCTP is included as a positive control. Uptake of [32P]dCTP was most affected by the triphosphate of deoxycytidine (dCTP), while the diphosphate form (dCDP) exhibited a moderate effect. In contrast, the nucleoside deoxycytidine and its monophosphate derivative (dCMP) had little effect on [32P]dCTP uptake (<10% inhibition). Thus, the reconstituted transporter discriminates between different phosphate forms of deoxycytidine. The uptake of alpha - and gamma -labeled [32P]dCTP into proteoliposomes and the effect of excess dCDP and dCMP on uptake suggests that dCTP is the primary substrate used for transport.

                              
View this table:
[in this window]
[in a new window]
 
Table III
Effect of competitors and inhibitors on the uptake of [32P]dCTP by proteoliposomes
Competitors were added immediately before the radiolabeled substrate. Atractyloside and NEM were added at a concentration of 1 mM 3 min before the labeled substrate. Proteoliposomes were prepared after HPT and blue Sepharose chromatography as described under "Experimental Procedures." Transport was started by the addition of 10 µM [alpha -32P]dCTP to proteoliposomes in a buffer containing 20 mM Hepes (pH 7.0), 0.2 mM EDTA, and 2 mM CaCl2. The concentration of competitors was 100 µM. Phosphate was added at a concentration of 5 mM. Means and S.D. values from three experiments in duplicate are presented.

The effects of other nucleoside triphosphates on [32P]dCTP uptake are shown in Table IV. At equimolar concentrations, the purines GTP, ATP, dATP, and dGTP moderately reduced [32P]dCTP uptake in proteoliposomes with more potent inhibition with a 5-fold excess of competitor. Interestingly, these purines were more effective than TTP or UTP in competing for [32P]dCTP uptake in proteoliposomes. These results raise the possibility that the observed transport activity may not be specific for dCTP only but may reflect the activity of a general dNTP carrier. Further studies will be required to assess if the competition represents uptake of other dNTPs.

                              
View this table:
[in this window]
[in a new window]
 
Table IV
Effect of nucleoside triphosphates on dCTP transport activity
The protein eluate from HPT and blue Sepharose chromatography was reconstituted into phospholipid vesicles as described under "Experimental Procedures." Transport was initiated by the addition of 10 µM [alpha -32P]dCTP and one of the competing nucleotides. Means and S.D. values from three separate experiments are presented. The control value of dCTP uptake was 189 pmol/min/mg protein.

The sensitivity of the reconstituted carrier to externally added inhibitors was investigated using the sulfhydryl reagent N-ethylmaleimide (a potent inhibitor of the phosphate carrier) (32), atractyloside (a specific inhibitor of the AAC) (33), and phosphate. N-Ethylmaleimide, atractyloside, and phosphate had no significant inhibitory effect on dCTP transport (Table III). However, a 50% increase in dCTP uptake occurs in the presence of atractyloside. The mechanism by which atractyloside increases dCTP uptake is unclear. These data indicate that the phosphate carrier and the AAC do not play a role in the dCTP uptake activity observed in this study. We have not assessed the uptake of other dNTPs, although it is possible that there are other carrier activities for these metabolites. To our knowledge, this is the first report of a preparation of a mitochondrial dCTP carrier activity in functional form from any source.

This transport activity suggests an important role of bioactive endogenous dNTP uptake in mitochondria. Thus, cytoplasmic pools of dNTPs may be available to mitochondria, which are continually being damaged, and for replication of their DNA. The transport activity reported in this study may also be important in mediating the mitochondrial accumulation of cytotoxic nucleoside analogs used in chemotherapy. Clinical and laboratory findings have focused attention on damage to mitochondrial function as a mechanism of toxicity of various drugs. Indeed, available evidence supports the hypothesis that the myopathy induced by anti-human immunodeficiency virus nucleoside analogs is due to inhibition of mitochondrial DNA synthesis (34, 35). The existence of the mitochondrial dCTP carrier activity described in this study may provide insight into the molecular mechanism underlying nucleoside analog-induced mitochondrial toxicity and protection.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants F32GM17474 (to E. G. B.) and AI-38204 (to Y. C. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger These two authors contributed equally to this work.

§ To whom correspondence should be addressed: Dept. of Pharmacology, Yale University School of Medicine, P.O. Box 802066, New Haven, CT 06520. Tel.: 203-785-7119; Fax: 203-785-7129; E-mail: cheng.lab{at}yale.edu.

    ABBREVIATIONS

The abbreviations used are: AAC, ATP/ADP carrier; HPT, hydroxyapatite.

2 E. G. Bridges, Z. L. Jiang, and Y. C. Cheng, unpublished observations.

    REFERENCES
Top
Abstract
Introduction
References

  1. Kramer, R., and Palmieri, F. (1994) Biochim. Biophys. Acta 974, 1-23
  2. LaNoue, K. F., and Schoolwerth, A. C. (1979) Annu. Rev. Biochem. 48, 871-922[CrossRef][Medline] [Order article via Infotrieve]
  3. Klingenberg, M. (1993) J. Bioenerg. Biomembr. 25, 447-457[Medline] [Order article via Infotrieve]
  4. Joyal, J. L., and Aprille, J. R. (1992) J. Biol. Chem. 267, 19198-19203[Abstract/Free Full Text]
  5. Kaplan, R. S., Pratt, R. D., and Pedersen, P. L. (1986) J. Biol. Chem. 261, 12767-12773[Abstract/Free Full Text]
  6. Parsons, P., and Simpson, M. V. (1973) J. Biol. Chem. 248, 1912-1919[Abstract/Free Full Text]
  7. Enriquez, J. A., Ramos, J., Perez-Martos, A., Lopez-Perez, M. J., and Montoya, J. (1994) Nucleic Acids Res. 22, 1861-1865[Abstract]
  8. Chang, C. N., Skalski, V., Zhou, J. H., and Cheng, Y. (1992) J. Biol. Chem. 267, 22414-22420[Abstract/Free Full Text]
  9. Chen, C. H., and Cheng, Y. C. (1992) J. Biol. Chem. 267, 2856-2859[Abstract/Free Full Text]
  10. Darley-Usmar, V. M., Rickwood, D., and Wilson, M. T. (1987) Mitochondria: A Practical Approach, pp. 143-144, IRL Press Ltd., Oxford
  11. Schafer, J. A., Giebisch, G., Kristensen, P., and Ussing, H. H. (1994) Methods in Membrane and Transporter Research, p. 325, R. G. Landes Co., Austin, TX
  12. Kramer, R., and Klingenberg, M. (1979) Biochemistry 18, 4209-4215[Medline] [Order article via Infotrieve]
  13. Kasahara, M., and Hinkle, P. C. (1977) J. Biol. Chem. 252, 7384-7390[Medline] [Order article via Infotrieve]
  14. Pick, U. (1981) Arch. Biochem. Biophys. 212, 186-194[Medline] [Order article via Infotrieve]
  15. Banerjee, R. K., and Datta, A. G. (1983) Mol. Cell. Biochem. 50, 3-15[Medline] [Order article via Infotrieve]
  16. Parker, W. B., and Cheng, Y. C. (1994) J. NIH Res. 6, 57-61
  17. Claeys, D., and Azzi, A. (1989) J. Biol. Chem. 264, 14627-14630[Abstract/Free Full Text]
  18. Wehrle, J. P., and Pedersen, P. L. (1983) Arch. Biochem. Biophys. 223, 477-483[Medline] [Order article via Infotrieve]
  19. Bisaccia, F., and Palmieri, F. (1984) Biochim. Biophys. Acta 766, 386-394[Medline] [Order article via Infotrieve]
  20. Kolbe, H. V. J., Costello, D., Wong, A., Lu, R. C., and Wohlrab, H. (1984) J. Biol. Chem. 259, 9115-9120[Abstract/Free Full Text]
  21. Kaplan, R. S., and Pedersen, P. L. (1985) J. Biol. Chem. 260, 10293-10298[Abstract/Free Full Text]
  22. Klingenberg, M., Riccio, P., and Aquila, H. (1978) Biochim. Biophys. Acta 503, 193-210[Medline] [Order article via Infotrieve]
  23. Stipani, I., and Palmieri, F. (1983) FEBS Lett. 161, 269-274[CrossRef][Medline] [Order article via Infotrieve]
  24. Rojo, M., and Wallimann, T. (1994) Biochim. Biophys. Acta 1187, 360-367[Medline] [Order article via Infotrieve]
  25. Alberty, R. A. (1969) J. Biol. Chem. 244, 3290-3302[Abstract/Free Full Text]
  26. Iwasaki, H., Huang, P., Keating, M. J., and Plunkett, W. (1997) Blood 90, 270-278[Abstract/Free Full Text]
  27. Xie, K. C., and Plunkett, W. (1996) Can. Res. 56, 3030-3037[Abstract]
  28. Gandhi, V., Mineishi, S., Huang, P., Yang, Y., Chubb, S., Chapman, A. J., Nowak, B. J., Hertel, L. W., and Plunkett, W. (1995) Semin. Oncol. 22, 61-67[Medline] [Order article via Infotrieve]
  29. Friland, A., Connelly, M. C., and Ashmun, R. (1990) Mol. Pharmacol. 37, 665-670[Abstract]
  30. Heinemann, V., and Plunkett, W. (1989) Biochem. Pharmacol. 38, 4115-4121[Medline] [Order article via Infotrieve]
  31. Gao, W. Y., Cara, A., Gallo, R. C., and Lori, F. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8925-8928[Abstract]
  32. Stappen, R., and Kramer, R. (1994) J. Biol. Chem. 269, 11240-11246[Abstract/Free Full Text]
  33. Arnaudo, E., Dalakas, M. C., Shanske, S., Moraes, C. T., DiMauro, S., and Schon, E. A. (1991) Lancet 337, 508-510[Medline] [Order article via Infotrieve]
  34. Casademont, J., Barrientos, A., Grau, J. M., Pedrol, E., Estivill, X., Urbano-Marques, A., and Nunes, V. (1996) Brain 119, 1357-1364[Abstract]
  35. Lewis, W., Simpson, J. F., and Myer, R. R. (1994) Circulation Res. 74, 344-348[Abstract]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.